Dr. Barry Dworkin

Possible new treatment, pending Phase 3 study confirmation, for Dupuytren’s Disease reported by Oxford researchers.

Medical Mythbusting Commentary for May 17, 2022

Source:
Breakthrough In Treatment For Dupuytren’s Disease As Clinical Trial Shows Efficacy Of anti-TNF Drug

Reference:
Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Related posts:

  1. Study adds evidence that bone drugs for osteoporosis work, are safe
  2. Osteoporosis treatment study in men shows reduction in vertebral fractures
  3. New treatment established for rare childhood blood vessel disease of the brain
  4. New medication for Hodgkin's patients who have failed to respond to all other treatments may soon be approved